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Insilico toxicologyinitsbroadestsensemeans“anythingthatwecandowithacomputerin
toxicology.” Many different types of in silico methods have been developed to characterize
and predict toxic outcomes in humans and environment. The term non-testing methods
denote grouping approaches, structure–activity relationship, and expert systems. These
methods are already used for regulatory purposes and it is anticipated that their role will
be much more prominent in the near future.This Perspective will delineate the basic prin-
ciples of non-testing methods and evaluate their role in current and future risk assessment
of chemical compounds.
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INTRODUCTION
We live in a world of chemicals. More than 60 million chemi-
cal compounds were known to exist as of 26 May 2011 (CAS1).
Fortunately we are exposed to only a fraction of these during
our lifetime. These include inadvertent exposures, e.g., pesti-
cide residues and products of chemical industries, and deliberate
exposures, e.g., cosmetics and drugs. Toxicology as a science and
regulatory tool has the goal of ensuring the safety of humans,ani-
mals, and the environment. Assessment or risks of all categories
of chemicalsforeigntothebody(xenobiotics)isstillmainlybased
on animal experimentation. However, developments in knowl-
edge of general pathophysiology, cellular pathways, genetics, and
computer-supported modeling, have resulted in a better under-
standing of the molecular mechanisms of xenobiotic action and
toxicity. Key elements in the integrated risk assessment approach
are the evaluation of chemical functionalities representing struc-
turalalertsfortoxicactions,theconstructionof kineticmodelson
thebasisof non-animaldata,andmorespeciﬁctestsforevaluating
cell toxicity (Boobis et al., 2002; Nigsch et al.,2009).
In this Perspective I will introduce the concept of in silico toxi-
cologyandhaveamoredetailedlookintotheso-callednon-testing
methods and their application in predicting biokinetic and target
organtoxicitypropertiesof compounds.Iwillalsoattempttopre-
dicthowthesemethodswillbeimplementedinthenearandmore
distant future in chemical safety evaluation. Technical jargon is
avoided as this Perspective is aimed to the reader not familiar with
the ﬁeld.
WHAT IS IN SILICO TOXICOLOGY?
In silico, a phrase coined as an analogy to the familiar phrases
in vivo and in vitro,is an expression used to denote“performed on
computer or via computer simulation.” In silico or computational
1www.cas.org
toxicology is an area of very active development and great poten-
tial. In silico toxicology is difﬁcult to deﬁne exactly, as today prac-
tically all toxicological research and risk assessment have major
insilico components.TheUnitedStatesEnvironmentalProtection
Agency (US EPA) deﬁnes in silico toxicology as the“integration of
moderncomputingandinformationtechnologywithmolecularbiol-
ogy to improve agency prioritization of data requirements and risk
assessment of chemicals”(US EPA, 2003).
HartungandHoffmann(2009)deﬁnedinsilicomethodologies
more liberally as“anything we can do with a computer in toxicol-
ogy, and there are few tests that would not fall into this category,
as most make use of computer-based planning and/or analysis.”
They identiﬁed nine different types of in silico approaches, of
which I will concentrate on what are called non-testing methods
in the European Union (EU) vocabulary and the application of
these methods in toxicity testing and regulation of chemicals.
In silico toxicology differs from traditional toxicology in many
ways, but perhaps the most important is that of scale. Scale in the
numbers of chemicals that are studied, breadth of endpoints and
pathways covered,levels of biological organization examined,and
rangeof exposureconditionsconsideredsimultaneously(Kavlock
et al.,2008).
DRIVERS OF IN SILICO TOXICOLOGY
There are several scientiﬁc, economical, and societal drivers
involving governments, academia, and industry, which promote
development and use of in silico methods in toxicology.
A major portion of in silico technology was developed by the
pharmaceutical industry for use in drug discovery. Environmen-
tal chemicals differ from drug candidates in many crucial ways.
Drugs are developed toward speciﬁc targets in the human (and
animal)body,aredesignedtopossessphysico-chemicalproperties
thataugmentabsorption,distribution,metabolism,andexcretion,
andhaveusepatternsthatareknownandquantiﬁable.Incontrast,
environmental chemicals generally are not designed with biologi-
cal activity in mind, cover extremely diverse chemical space, have
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poorly understood biokinetic proﬁles,and are generally evaluated
at exposures levels well in excess of likely real world situations.
Several different kinds of in silico methods have been devel-
oped and applied in the academia and pharmaceutical industry
to model pharmacodynamic, pharmacokinetic, and toxicologi-
cal hypothesis development and testing. These in silico methods
include databases, different kinds of quantitative SAR (QSAR)
methods, pharmacophores, homology models and other molecu-
larmodelingapproaches,machinelearning,datamining,network
analysis tools, and data analysis tools using computers. Different
types of physiologically based pharmacokinetic (PBPK) models
require also extensive computing. One should also make a dis-
tinctionbetweenfundamentally statisticalmethodsandmodeling
approaches that attempt to describe the underlying chemical or
biological system and use this approach to obtain predictions of
system-level behavior. A vast and rapidly growing literature and a
range of in silico tools are now available. Excellent recent reviews
ontheuseof insilico methodsindrugdevelopmentinclude(Ekins
et al., 2007a,2007b; Muster et al., 2008; Kortagere et al., 2009;
Valerio, 2009; Cook, 2010; Merlot,2010).
OneofthegoalsoftheEuropeanpublic–privateinitiativeInno-
vativeMedicinesInitiative(IMI)istodevelopinsilico methodsfor
predicting conventional and recently recognized types of toxicity
(IMI, 2010). The IMI project eTOX (Integrating bioinformatics
and chemoinformatics approaches for the development of expert
systems allowing the in silico prediction of toxicities) aims to
develop a drug safety database from the pharmaceutical industry
toxicologyreportsandpublictoxicologydata,innovativemethod-
ological strategies, and novel software tools to better predict the
toxicological proﬁles of small molecules in early stages of the drug
development process.
Currently, there is no speciﬁc US Food and Drug Administra-
tion (FDA) guidance dedicated to the use of these tools in the
development of drugs. Computational toxicology data are sub-
mitted on a voluntary basis and are not required (Valerio, 2009).
The situation is very similar with the European MedicinesAgency
(EMA).
In2006,theEUcompletelyreviseditsregulatoryframeworkfor
chemicals with the passage of the regulation (EC, 2006.European-
Comm:2006) concerning registration, evaluation, authorization,
and restriction of chemicals (REACH). Alternative testing meth-
odsareurgentlyneededtofulﬁllthegoalofreducinganimaltesting
inREACH.TheREACHregulationmentionsnon-testingmethods
for“predictivetoxicology”inriskassessmentof commercialchemi-
calsintheEU.Theregulation(EC,2008.EuropeanComm:2008)on
test methods to be applied for the purposes of REACH embraces
a very limited set of in silico methods, but the Guidance on infor-
mation requirements and chemical safety assessment issued by
theEuropeanChemicalsAgency(ECHA)givesverydetailedback-
ground information and recommendations for use of non-testing
methods and grouping of chemicals (ECHA, 2008).
The seventh amendment to the EU Cosmetics Directive
(EC, 1976.EuropeanComm:1976) foresees a regulatory frame-
work with the aim of phasing out animal testing. The market-
ing ban has been in effect since March 2009 for all cosmetic
ingredients investigated by animal studies intended to predict
human health effects,with the exception of repeated-dose toxicity
(including skin sensitization and carcinogenicity), reproductive,
and developmental toxicity and toxicokinetics, for which the
deadline is extended to 2013.
In the United States, the US National Research Council (NRC,
2007) report proposed an approach to assessing environmental
chemicals based on identifying human toxicity pathways, model-
ing and interpreting these pathways using cellular and computa-
tional systems, and predicting levels of human exposure that are
not likely to be associated with adverse effects. A key issue in the
report is the use of systems biology and the “omics” approaches
in identifying toxicity pathways as the basis for new methodolo-
gies in toxicity testing and dose response modeling, together with
the application of computational modeling of toxicokinetics and
toxicodynamics (Blaauboer, 2008; Andersen and Krewski, 2009;
Valerio, 2009).
The NRC report envisions a future in which virtually all rou-
tine toxicity testing would be conducted in human cells or cell
linesinvitro byevaluatingcellularresponsesinabatteryoftoxicity
pathwayassaysusinghigh-throughputtests.Obviously,challenges
exist in ensuring that the suite of assays provides sufﬁcient cov-
erage of toxicity pathways so as to capture the broad range of
possible pathway perturbations. The identiﬁcation and character-
ization of these pathways is not the sole province of the toxicology
community; most research into these pathways comes from, and
will continue to arise from,contemporary cell biology. These cell-
signaling pathways are being enumerated through mechanistic
studies from front-line biologists interested in responses of cells
and organisms to various stressors (Kavlock et al.,2008;Andersen
and Krewski, 2009).
NON-TESTING METHODS
According to the ECHA Guidance on information require-
ments and chemical safety assessment (ECHA,2008),non-testing
data can be generated by three main approaches: (1) grouping
approaches,which include read-across and chemical category for-
mation;(2)structure–activityrelationship(SAR)andquantitative
SAR (QSAR,a term used in the following text to imply both); and
(3) expert systems. The development and application of all kinds
ofnon-testingmethodsisbasedonthesimilarityprinciple,i.e.,the
hypothesis that similar compounds should have similar biological
activities.
In more general terms, non-testing methods can be divided
into two main classes, i.e., comprehensive (global) and speciﬁc
(local) ones. Comprehensive methods, also called expert systems,
mimic human reasoning and formalize existing knowledge. Pre-
dictive expert systems portray properties of a compound based
onknowledgerules.ExpertsystemshaveanadvantageoverQSAR
methods in that prediction is related to speciﬁc mechanisms. Spe-
ciﬁc systems generally apply to a narrow range of targets, e.g.,
speciﬁc receptors or enzymes.
Speciﬁc methods can be divided to ligand-based and target-
based techniques. Ligand-based modeling such as QSAR involves
active ligands without considering the 3-dimensional (3D) struc-
ture of the protein and the possible sites of interaction. QSAR is
a mathematical model that correlates a quantitative measure of
chemical structure to either a physical property or a biological
effect (e.g., toxic outcome). The term quantitative in QSAR refers
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to the nature of the parameters (also called descriptors) used to
make the prediction. A molecular descriptor provides a means of
representing molecular structures in a numerical form. The num-
ber may be a theoretical attribute (e.g. relating to size or shape) or
ameasurableproperty.Linearregressionanalysisisoftenusedbut
a variety of other multivariate statistical techniques are also used.
Structure-based methods calculate atomic interactions
between ligands and their target macromolecules. They require
3Dstructuresof bothligandsandmacromoleculesandneedmore
computational power. Algorithms from target- and ligand-based
approachescanbeintegratedtogainadditionalstructuralinsights
and to further validate the individual models. Today ligand- and
target-based methods are often combined (Höltje et al.,2003; van
de Waterbeemd and Gifford, 2003; Johnson and Rodgers, 2006;
Lewis and Ito, 2008).
Registration, evaluation, authorization, and restriction of
chemicals opens the possibility of evaluating chemicals not only
on a one-by-one basis,but by grouping chemicals in categories. In
the ECHA Guidance (ECHA, 2008), the terms category approach
and analog approach are used to describe techniques for grouping
chemicals, whilst the term read-across is reserved for a technique
of ﬁlling data gaps in either approach. These approaches involve
categorizing potential chemical analogs based upon their degree
of structural, reactivity, metabolic, and physico-chemical similar-
ity to the chemical with missing toxicological data. It extends
beyond structural similarity by including differentiation based
upon chemical reactivity and addressing the potential that an
analog and target molecule could show toxicologically signiﬁcant
metabolic convergence or divergence. In addition, it identiﬁes
differences in physico-chemical properties, which could affect
bioavailability and consequently biological responses observed
in vitro or in vivo. The approach provides a stepwise decision
tree for categorizing the suitability of analogs, which qualitatively
characterizes the strength of the evidence supporting the hypoth-
esis of similarity and level of uncertainty associated with their use
for read-across. The chemical category and QSAR concepts are
strongly connected. The concept of forming chemical categories
and then using measured data on a few category members to esti-
mate the missing values for the untested members is a common
sense application of QSAR. The reason this concept is so com-
patible with QSAR is that this broad description of the categories
concept and the historical description of QSAR are one and the
same (ECHA, 2008;Wu et al.,2010).
TOXICOKINETICS, XENOBIOTIC METABOLISM, AND
STRUCTURAL ALERTS
The term ADME refers to absorption, distribution, metabolism,
and excretion, the four processes related to the pharmacokinetic
proﬁle of substances interacting with living organisms. In toxicol-
ogy, ADME is often called toxicokinetics or biokinetics. Collec-
tively, these processes determine the fate of the substance inside
the body. The term ADMET is used to express the overall pro-
ﬁling of ADME properties and toxic effects of a substance. The
ADME properties of compounds are important in discriminat-
ing between the toxicological proﬁles of parent compounds and
their metabolites or degradation products. Metabolism plays a
crucial role in pharmacological and toxicological effects caused by
xenobiotics.Therearetwofacetstometabolism.First,metabolism
leads to termination of the action of a compound and renders it
excretablefromthebody.Second,thesamesystemsometimespro-
duces metabolites that are toxic. In these cases parent compounds
areoftentransformedintoreactiveelectrophiles,whichbindcova-
lently with proteins and DNA. Formation of reactive metabolites
is the main initial mechanism of chemical carcinogenesis and also
explains a large proportion of the so-called idiosyncratic drug
adverse reactions (Liebler and Guengerich, 2005; Walker et al.,
2009).
The cytochrome P450 (CYP) enzymes constitute a large super-
family of heme proteins capable of metabolizing a vast number
of exogenous and endogenous compounds. About 10 CYP forms
are responsible for the metabolism of xenobiotics in humans. The
CYPs metabolize, e.g., polycyclic aromatic hydrocarbons (ambi-
ent air), aromatic amines (occupational exposure), heterocyclic
amines (food), pesticides and herbicides, and virtually all drugs.
Ligands to CYP enzymes are either substrates, i.e., are metabo-
lized by the enzyme, or act as inhibitors and thus block substrate
turnover (Pelkonen et al., 2008). Recent progress in molecular
modeling of CYP enzymes demonstrate that it is possible to gen-
eraterealisticmodelsforthexenobioticmetabolizinghumanCYPs
that compare favorably with crystal structures, and thus may be
used to derive substrate binding energies that agree closely with
experimental kinetic values (Stjernschantz et al., 2008; Pelkonen
et al., 2009). A workshop sponsored by European Centre for
the Validation of Alternative Methods (ECVAM; Coecke et al.,
2006) identiﬁed lack of knowledge in metabolism aspects as a
key bottleneck in the development of in vitro toxicity tests.
Many functional groups in chemical structures are known to
be associated with formation of reactive metabolites, very often
catalyzed by the CYP enzymes. However, not all compounds with
suchfunctionalgroupsaretoxic,sinceformationof reactiveinter-
mediates is limited by the ability of CYPs to activate them. In this
process, the orientation of the compound in the enzyme active
site is critical, as only compounds with speciﬁc steric and elec-
trostatic properties will orientate critical atoms toward the heme
iron(Hollenbergetal.,2008).Thecrystalstructuresarenowavail-
able for several mammalian CYP enzymes. These structures allow
visualizingthedockingof ligandsinCYPproteins.However,these
snapshots do not provide a complete picture. Based on compar-
isonsbetweensubstrate-freeandsubstrate-boundCYPstructures,
it can be concluded that substrate binding causes conformational
changes in the enzyme, the extent of which is dependent on the
natureofthesubstrateandtheCYPinvolved(IsinandGuengerich,
2008).
The need to assess the ability of a chemical to act as a mutagen
oragenotoxiccarcinogen(collectivelytermedgenotoxicity)isone
of theprimaryrequirementsinregulatorytoxicology.Akeystepin
thedevelopmentofchemicalcategoriesforgenotoxicityisdeﬁning
the organic chemistry associated with the formation of a cova-
lentbondbetweenDNAandanexogenouschemical.Thisorganic
chemistryistypicallydeﬁnedasstructuralalerts.Inarecentpaper,
EnochandCronin(2010)identiﬁed57structuralalertsassociated
withmutagenicityandgenotoxiccarcinogenicity.Importantly,the
identiﬁcation of 22 new structural alerts identiﬁed from idiosyn-
cratic drug toxicity data has signiﬁcantly improved the coverage
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of the chemical universe to which these alerts can be applied. In
contrasttothehistoricalalertcompilations,thisworkhastakenan
additional step, and compiled the detailed mechanistic chemistry
reaction associated with each of the alerts into a single source.
Several commercial and public in silico methods are available
for assessing ADMET properties. These methods predict com-
pound physico-chemical properties,gastrointestinal permeability,
blood–brain barrier permeability, binding to plasma proteins,
afﬁnity for transporter proteins, metabolic clearance, potential to
inhibit or induce drug metabolizing enzymes (especially CYPs),
and generation of reactive metabolites. A report on alternative
methodsforcosmeticstesting(Adleretal.,2011) concluded that a
whole array of in vitro/in silico methods at various levels of devel-
opment is available for most of the steps and mechanisms which
govern the toxicokinetics of cosmetic substances. One exception
is renal excretion for which until now no in vitro/insilico methods
are available; thus there is an urgent need for further develop-
ments in this area. The same limitations apply to testing all other
chemical compounds to which we are exposed.
BIOKINETIC MODELING AND INTEGRATION OF DATA
Indrugdevelopmentandenvironmentaltoxicology,PBPKmodel-
ing has become a cornerstone approach to organize and integrate
input from in vivo, in vitro, and in silico studies. PBPK models
can be used to predict concentration–time proﬁles if their para-
meter values can be determined from in vitro data, or in vivo
data in humans, from QSAR models, or from the scientiﬁc litera-
ture. PBPK models are evolved compartmental models which try
to use realistic biological descriptions of the determinants of the
disposition of a chemical compound in the body (Loizou et al.,
2008).
Analogously, the advancements made in physiologically based
biokinetic (PBBK) modeling have substantially increased the pos-
sibilities to give a better interpretation of in vitro and in silico
toxicitydatafortheirrelevanceintermsofatoxicdoseintheinvivo
situation. These models are usually used to estimate the concen-
tration in a particular tissue, given a certain dose (or external
exposure pattern). And vice versa, an effective toxic concentra-
tion determined in a relevant in vitro system (i.e., relevant for the
toxic effect in the target tissue) can be used as input in the PBBK
model to estimate the external dose that would result in the effec-
tive concentration in the target tissue (Blaauboer,2008; Pelkonen,
2010).
The concept of integrated testing as deﬁned by Blaauboer et al.
(1999) applies also today: “An integrated testing strategy is any
approach to the evaluation of toxicity which is based on the use
of two or more of the following:physicochemical,in vitro,human
(e.g.,epidemiological,clinical case reports),animal data (as avail-
able or if unavoidable), computational methods, structural alerts
and kinetic models.”
In practice, in silico predictions are not used in isolation. They
already constitute a part of the weight of evidence approach,or an
integrated testing strategy. An evidence based approach involves
an assessment of the relative values/weights of different pieces of
the available information that have been retrieved and gathered.
These weights/values can be assigned either in an objective way
by using a formalized procedure or by using expert judgment.
The weight given to the available evidence will be inﬂuenced by
factorssuchasthequalityof thedata,consistencyof results,nature
and severity of effects, relevance of the information for the given
regulatory endpoint (ECHA, 2010).
VALIDATION OF METHODS
Models and simulations without experimental data are empty
exercises, so the experimental data must be correct and repro-
ducible (Pelkonen, 2010). There is widespread agreement that
in silico models should be scientiﬁcally valid or validated if they
are to be used in the regulatory assessment of chemicals. In the
EU, the concept of scientiﬁcally valid model is incorporated into
the REACH text. Since the concept of validation is incorporated
into legal texts and regulatory guidelines,it is important to clearly
deﬁne what it means, and to describe what the validation process
mightentail.Forthepurposesof REACH,anassessmentof QSAR
model validity should be performed by reference to the inter-
nationally agreed principles for the validation of QSARs. The
validationexerciseitself maybecarriedoutbyanypersonororga-
nization,but it will be the industry registrant of the chemical who
needs to argue the case for using the QSAR data in the context of
the registration process. This is consistent with a key principle of
REACH that the responsibility for demonstrating the safe use of
chemicals lies with industry (ECHA, 2008). It should be empha-
sized that the ECVAM is not mandated to carry out validation of
in silico methods.
The principles for QSAR validation by the Organisation for
Economic Co-operation and Development (OECD, 2004.OECD-
Princi:2004) state that in order:“to facilitate the consideration of a
(Q)SAR model for regulatory purposes, it should be associated with
the following information:
1. a deﬁned endpoint;
2. an unambiguous algorithm;
3. a deﬁned domain of applicability;
4. appropriate measures of goodness-of-ﬁt, robustness and
predictivity;
5. a mechanistic interpretation, if possible.”
A guidance document has been produced to provide practical
guidance on the interpretation of these OECD principles (OECD,
2007).
An important issue in model validation is the deﬁnition of
its applicability domain. The applicability domain of a QSAR is
thephysico-chemical,structuralorbiologicalspace,knowledgeor
informationonwhichthetrainingsetofthemodelhasbeendevel-
oped, and for which it is applicable to make predictions for new
compounds. Therefore QSAR models are associated with limita-
tions as to what they can reliably be used (Jaworska et al.,2005).A
valid QSAR will be associated with at least one deﬁned applicabil-
ity domain in which the model makes estimations with a deﬁned
level of accuracy (reliability). When applied to chemicals within
its applicability domain, the model is considered to give reliable
results(ECHA,2008).Theultimatecaseoffallingoutoftheapplic-
ability domain is stated in the old saying in computing sciences:
“garbage in, garbage out.” In other words, input of inappropriate
(or poor quality) data will give false results.
Frontiers in Pharmacology | PredictiveToxicity June 2011 | Volume 2 | Article 33 | 4Raunio In silico toxicology
Despite the signiﬁcant advancements of several independent
validationstudies,theuseofinsilicotoolsmustbetakencautiously
inthecontextof theircurrentcapabilityduetothequalityof avail-
able bioassay data, lack of widespread understanding of model
construction (the black box dilemma), limited chemical space of
training data sets (i.e., limited applicability domain), and high
potentialformultiplemechanismsof compoundtoxicitythatcan-
not at present be modeled. These uncertainties in the technology
do not render the approaches useless but point out they should be
cautiously taken into consideration. There may be a workable bal-
ance in terms of customized computational platforms amenable
to the hazard identiﬁcation and risk characterization processes
for obtaining desired performance of a model (e.g., sensitivity vs.
speciﬁcity;Valerio, 2009).
IMPLEMENTATION
Althoughtechnicalprogresshasbeenrapid,regulatoryacceptance
of QSAR approaches has been slow. The situation is changing as
there is now a clear regulatory need for the use of QSAR. The
improved in silico technologies in regulatory toxicology presents
an opportunity to bridge the communication gap between toxi-
cologists and QSAR experts. The extensive work which is going
on to further develop mechanistic understanding of toxicological
effects seen in vivo and in vitro is a reason for optimism.
There are currently no internationally accepted in silico alter-
native in the sense of a full replacement for all testing of a speciﬁc
hazard. Regulatory use so far has been limited mainly to pri-
oritization of test demands or ﬁlling data gaps in some cases,
especially for low risk chemicals (Hartung and Hoffmann, 2009).
It should be stressed that QSAR estimates are already used rou-
tinely for predicting some key environmental fate parameters of
organic substances, partly because the experimental determina-
tion of these parameters can be difﬁcult and/or expensive, and
partly because the information is not normally required in the
regulatory submissions (ECHA, 2008).
The REACH regulation leaves a lot of room to practical
implementation of in silico tools (EC,2006.EuropeanComm:2006;
Schaafsma et al.,2009). Classiﬁcation of substances,especially for
existing high-production volume substances, based only on com-
putationaltoxicologyisatthisstagehighlyunlikely,especiallysince
regulatory implementation is a consensus process. Broad waiving
of testing for REACH because of negative in silico results is also
rather unlikely, since not even validated cell systems are generally
accepted for this. The most likely use in the mid-term will be the
intelligentcombinationofinvitro,insilico,andinvivoinformation
(Hartung and Hoffmann, 2009).
The process of QSAR acceptance under REACH will involve
initial acceptance by industry and subsequent evaluation by the
authorities, on a case-by-case basis. It is not foreseen that there
will be a formal adoption process,in the same way that test meth-
ods are currently adopted in the EU and OECD. In other words,it
is not anticipated that there will be an ofﬁcial, legally binding list
of QSAR methods (ECHA, 2008).
The REACH principles induced the emergence of a compara-
bleprogramfromtheUSEPAnamedToxCast(USEPA2).ToxCast
2www.epa.gov/comptox/toxcast
promotes“theapplicationof ComputationalToxicologytoassessthe
risk chemicals poses to human health and environment.” The cur-
rent emphasis in the ToxCast program, which uses a variety of
high-throughput tests and in silico methods, is on prioritization
of compounds for targeted testing in animals.
Thus, regulatory ofﬁcials in the EU and US agree on the need
to modernize toxicological testing, but they have taken somewhat
differentapproaches.Severaltrans-Atlanticcooperativeeffortsare
alreadyinplacetohelpbridgethegap.Researchcollaborationwas
between the US Environmental Protection Agency (EPA) and the
EuropeanCommissionJointResearchCentre’sInstituteforHealth
andConsumerProtection(IHCP).Thecommonthemeofthiscol-
laboration,basedonsharinghigh-throughputtoxicologicalproﬁle
data and data from integrated testing strategies based on compu-
tational and in vitro methods, is the shift toward a “toxicological
pathway based hazard assessment”(IHCP, 2010.Institutef:2010).
A wide variety of publicly available and commercial computa-
tional tools has been developed that are suitable for the develop-
ment and application of QSARs. Such tools include methods for
a range of QSAR-related tasks, including data management and
data mining, descriptor generation, molecular similarity analy-
sis, analog searching, and hazard assessment. Due to the limited
availability of freely accessible in silico software, there is a need
to develop a range of transparent and open-source tools, which
should eventually be available to all stakeholders in the regulatory
process (especially industry and authorities). A prime example
of such an open-access tool is the (Q)SAR Application Toolbox
developed by OECD.
Table 1 lists examples of projects, organizations, and open-
access software promoting use of in silico methods in toxicology.
More comprehensive lists are available in review articles (Hou
and Wang, 2008; Pelkonen et al., 2009;Valerio, 2009; Wang, 2009;
Mostrag-Szlichtyng and Worth, 2010) and the ECHA guidance
(ECHA, 2008). An extensive list of in silico tools can be found at
the Swiss Institute of Bioinformatics Click2Drug homepage3.
PROS AND CONS OF IN SILICO APPROACHES
As with any testing approaches, non-testing methods have their
prosandcons.AccordingtoValerio(2009),theadvantagesofthese
methods compared with in vitro and especially in vivo approaches
include the following:
• higher throughput
• less expensive
• less time consuming
• constant optimization possible
• have higher reproducibility if the same model is used
• have low compound synthesis requirements
• have potential to reduce the use of animals
Limitations include (Weaver and Gleeson, 2008;Valerio, 2009):
• quality and transparency of training set experimental data
• transparency of the program (what is being modeled?)
• descriptors sometimes confusing
• applicability domain sometimes not clear
3www.click2drug.org
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Table 1 | Examples of in silico toxicology projects and tools.
Short description
EUAND US PROJECTS
ORCHESTRA A project funded by EC to disseminate recent research on computer-based methods for evaluating the toxicity of
chemicals.
www.orchestra-qsar.eu
CAESAR CAESAR was speciﬁcally dedicated to develop QSAR models for the REACH legislation.
www.caesar-project.eu
EPA ComputationalToxicology
Research Program (CompTox)
CompTox is working with partners to revolutionize how chemicals are currently assessed for potential toxicity
to humans and the environment. The CompTox Research Program conducts innovative research that integrates
advances in molecular biology, chemistry, and innovative computer science to more effectively and efﬁciently rank
chemicals based on risks.
www.epa.gov/ncct
ORGANIZATIONS
Ex-ECB ComputationalToxicology
Group
The ComputationalToxicology Group aims to promote the development, assessment, acceptance, and implemen-
tation of computer-based methods suitable for the regulatory assessment of chemicals.This includes methods for
predicting the effects of chemicals on human health and the environment, as well as their distribution and fate within
the environment and biological organisms.
http://ecb.jrc.ec.europa.eu/qsar
International QSAR Foundation The International QSAR Foundation is the only non-proﬁt research organization devoted solely to creating alternative
methods for identifying chemical hazards without further laboratory testing.
www.qsari.org
OPEN-ACCESS SOFTWARE
The OECD QSARToolbox The QSARToolbox is a software intended to be used by governments, the chemical industry and other stakeholders
to ﬁll gaps in (eco-)toxicity data needed for assessing the hazards of chemicals.TheToolbox incorporates information
and tools from various sources into a logical workﬂow. Grouping chemicals into chemical categories is crucial to this
workﬂow.The (Q)SARToolbox has been developed in collaboration with OECD and the ECHA.
www.qsartoolbox.org
VirtualToxLab VirtualToxLab is an in silico tool for predicting the toxic potential (endocrine and metabolic disruption, interference
with the hERG ion channel) of drugs, chemicals, and natural products. It simulates and quantiﬁes their interac-
tions toward a series of proteins known to trigger adverse effects using automated, ﬂexible docking combined with
multi-dimensional QSAR.
www.biograf.ch
Predicting Hazard, Characterizing
Toxicity Pathways, and Prioritizing
theToxicityTesting of Environmental
Chemicals (ToxCast)
In 2007 , EPA launched ToxCast to develop a cost-effective approach for efﬁciently prioritiz-
ing the toxicity testing of thousands of chemicals. Emphasis is on environmental chemicals.
www.epa.gov/comptox/toxcast
EPI Suite The EPI (Estimation Programs Interface) Suite™ is a Windows®-based suite of physical/chemical property and envi-
ronmental fate estimation programs developed by the EPA’s Ofﬁce of Pollution Prevention Toxics and Syracuse
Research Corporation (SRC).
http://www.epa.gov/opptintr/exposure/pubs/episuite.htm
• ADME features, especially metabolism, not taken into account
• carcinogenicity prediction does not work on non-genotoxic
compounds
To date, positive experiences with QSAR approaches (>70%
correct predictions, notably mostly not validated with external
datasets) have been reported mainly for mutagenicity, sensitiza-
tion,andaquatictoxicity,i.e.,areaswithrelativelywellunderstood
mechanisms,notforcomplex/multipleendpoints.Hepatotoxicity,
neurotoxicity, and developmental toxicity cannot be accurately
predicted with in silico methods. Here, the perspective lies in
breaking down complex endpoints into different steps or path-
ways with the common problem of how to validate these and put
them together to make one prediction (Hartung and Hoffmann,
2009; Merlot,2010).
CONCLUSION
“In silico tools have a bright future in toxicology.They add the objec-
tivity and the tools to appraise our toolbox. They help to combine
various approaches in more intelligent ways than a battery of tests”
(Hartung and Hoffmann, 2009).
It is evident that the requirements for reducing animal test-
ing in REACH and similar laws elsewhere in the world, together
with rapid technological progress and economic incentives, are
the main drivers of promoting use of in silico methods. Cur-
rently they play a role in providing mechanistic information and
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thus explaining underlying systems, but also in identifying test-
ing needs and setting testing priorities. The whole process of
implementing in silico methods into regulatory use is rapidly
evolving. In the near future, we will see more and more results of
in silico methods being included in risk assessment documents as
supporting data.
The current risk assessment methodologies for chemicals
regarding human toxicity endpoints are often derived from those
forpreclinicalstudiesof pharmaceuticals.Obviously,themethods
forhazardassessmentarelargelythesameforindustrialchemicals,
pesticides, and drug candidates. It is likely that in silico methods
will be used increasingly for the direct replacement of test data,as
relevant and reliable models become available, and as experience
in their use becomes more widespread. In the more distant future,
wemaywellwitnessagradualreplacementofsomeclassicalinvivo
tests by in vitro and in silico methods. Some in silico tools will be
useful, but not widely available, due to their proprietary nature.
Other tools are currently under development, or will need to be
developed in the near future.
Ideally, in silico results can be used as stand-alone evi-
dence for regulatory purposes if they are considered relevant,
reliable and adequate for the purpose, and if they are docu-
mented properly. In practice, there may be uncertainty in one
or more of these aspects, but this does not preclude the use
of the in silico estimate in the context of a weight of evidence
approach,inwhichadditionalinformationcompensatesforuncer-
tainties resulting from a lack of information on the in silico
method.
Final note: the term non-testing method, although probably
politically correct, is misleading in the sense that a lot of in vivo
and in vitro testing has gone into generating these methods, and
will need to do so in the future also.
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